Topic,Count,Name,Representation,Representative_Docs
-1,24,-1_small cell_pancreatic cancer_poor performance_negative breast,"['small cell', 'pancreatic cancer', 'poor performance', 'negative breast', 'important congresses', 'exciting time', 'elderly patients', '', '', '']","['The initial opportunity for IDHIFA is a bit more limited because if we start in relapsed refractory AML, our first line AML journey has started', 'In addition, there will be data from the ABOUND non-small cell lung cancer program with ABRAXANE in elderly patients and in patients with poor performance status', 'We expect results of the apact adjuvant pancreatic cancer trial to be available by the end of 2017. And the pivotal ABRAXANE (16:17) combination trials in non-small cell lung cancer and triple negative breast cancer will read out in 2018. The second quarter is always an exciting time with important congresses']"
0,69,0_late line_low risk_multiple myeloma_autologous stem,"['late line', 'low risk', 'multiple myeloma', 'autologous stem', 'later line', 'refractory myeloma', 'patient population', 'regulatory approval', 'relevant dose', 'clinical milestones']","['We have already achieved key regulatory and clinical milestones with the approval of REVLIMID as maintenance therapy post autologous stem cell transplantation', 'We are preparing to initiate pivotal programs for multiple additional assets by the end of this year, including marizomib in first line glioblastoma, BB2121 in relapsed refractory myeloma, JCAR017 in relapsed refractory large B-cell lymphoma, CC-122 in relapsed refractory lymphoma, IDHIFA in first line AML and durvalumab in myeloma, MDS and AML', 'Our ongoing Phase III luspatercept studies in later line low risk MDS and non-transfusion dependent beta-thalassemia, I expect it to be fully recruited during the second quarter, which represents an acceleration of six months versus original plan with an expected readout of top line results by mid 2018. In summary, we had a great start to the year for the Hematology and Oncology franchise and we are on track to deliver our 2017 guidance']"
1,27,1_net sales_sequential growth_strong sales_,"['net sales', 'sequential growth', 'strong sales', '', '', '', '', '', '', '']","['Finally, as mentioned on our Q4 call, we are successfully enrolling key development programs for POMALYST/IMNOVID to further support the use of multiple combinations', 'The underlying demand is very strong and total prescriptions grew in Q1 versus Q4. Demand growth was offset by the gross-to-net impact of the coverage gap and some inventory fluctuation', 'The (14:15) RELEVANCE and AUGMENT trials are both expected to read out by the end of 2017. POMALYST/IMNOVID net sales grow 33% year over year']"
